Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent.~* Gastric adenocarcinoma, including adenocarcinoma of the esophagogastric junction, histologically proven.~* Measureable metastatic disease.~* Male or female subjects, age 18 years and older.~* Karnofsky performance status score equal to or greater than 70.~* Life expectancy of at least 3 months.~* Subjects must be chemotherapy naïve.~* At least 6 weeks from prior curative radiotherapy and 3 weeks from surgery.~* Adequate hematological and coagulation parameters: hemoglobin\>9.5 g/dL; white blood cell count\>3x10\^9/L, platelets\> 100x10\^9/L; international normalized ratio of prothrombin time \<1.2, and activated partial thromboplastin time no more than 5 seconds above normal limits.~* Adequate clinical chemistry parameters: creatinine\<1.5mg/dL; total bilirubin\<1.5mg/dL; and aspartate aminotransferase and alanine aminotransferase \<2.5x upper normal levels.~* Able to comply with scheduled follow-up and with management of toxicity.~* Use contraceptive measures, if sexually active~Exclusion Criteria:~* Previous or current malignancies other than gastric adenocarcinoma, with the exception of adequately treated in situ carcinoma of the cervix, uteri, or nonmelanoma skin cancer~* Female subjects who are pregnant or nursing~* Female subjects with reproductive potential refusing a pregnancy test~* Any previous palliative chemotherapy, adjuvant or neoadjuvant chemotherapy, or investigational drug~* Any prior anticancer immunotherapy~* Immunodeficiency~* Bone marrow transplantation within 1 year~* Symptomatic peripheral neuropathy \> Grade 2 NCI-CTC, Version 2.0 criteria~* Severe hearing disorder \> Grade 2 NCI-CTC, Version 2.0 criteria~* Known dihydropyrimidine dehydrogenase deficiency~* Any other sever condition as defined by the following: unstable cardiac disease despite treatment; myocardial infarction within 6 months before study entry; history of significant neurologic or psychiatric disorders including dementia or seizures; active uncontrolled infection; active disseminated intravascular coagulation; or any other serious underlying medical conditions that could impair the ability of the subject to participate in the study~* Subjects who have previously demonstrated hypersensitivity to diphtheria toxoid~* Subjects who require chronic administration of corticosteroids~* Use in the past 30 days or concomitant use of immunosuppressants~* Use in the past 14 days or chronic concomitant use of proton pump inhibitors~* Subjects who have a history of hypercalcemia~* Subjects who cannot be regularly followed up for psychological, social, familial, or geographic reasons~* Subjects with expected noncompliance to toxicity management

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): See intervention description.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete